Workspaces
Log in Sign up

FDA Briefing Documents Cast Severe Doubt on Capricor's Deramiocel Ahead of High-Stakes AdCom

Updated

Sources

FDA Briefing Documents Cast Severe Doubt on Capricor's Deramiocel Ahead of High-Stakes AdCom

On July 27, 2026, the U.S. Food and Drug Administration (FDA) published highly critical briefing documents ahead of the July 29, 2026, Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting for Capricor Therapeutics' deramiocel (allogeneic cardiosphere-derived cells), an investigational therapy for cardiomyopathy in Duchenne muscular dystrophy (DMD). The documents sent Capricor's stock tumbling by over 65% as FDA reviewers directly disputed the company's claims of Phase 3 clinical success.

The regulatory friction centers on the pivotal Phase 3 HOPE-3 trial. While Capricor previously reported that the trial met its primary and secondary endpoints, the FDA's briefing materials flatly contradicted this, stating that the trial failed to demonstrate efficacy under its original pre-specified parameters. Furthermore, the agency criticized Capricor for making post-hoc, post-unblinding modifications to its statistical analysis plan (SAP)1 and raised concerns that a distinct adverse event profile may have compromised patient blinding.

Key Regulatory Criticisms
  • Statistical Analysis Plan (SAP) Discrepancies: The FDA revealed that after the completion of the randomized, double-blind portion of the HOPE-3 trial, Capricor made multiple post-hoc modifications to the pre-specified SAP during the trial's open-label extension. The FDA's efficacy evaluation relied on SAP version 1.1, under which the trial showed no statistically significant difference between deramiocel and placebo. Capricor's CEO Linda Marbán strongly objected to this, asserting that the company's positive efficacy results are governed by SAP version 3.0, which was finalized prior to unblinding and after the addition of a second cohort.
  • Blinding Concerns: The FDA highlighted a stark difference in hypersensitivity reactions between the treatment group (42%) and the placebo group (15%), noting that this distinctive safety profile could have allowed investigators or patients to infer their treatment assignments, undermining the double-blind design.
  • Substantial Evidence Standard: The FDA reiterated that a single trial with post-hoc analytical adjustments does not meet the standard of "substantial evidence of effectiveness," which typically requires two independent, well-controlled clinical investigations.

This development sets up an exceptionally contentious advisory committee meeting on July 29, where independent experts will debate whether the clinical data package provides sufficient evidence of effectiveness to support approval.

  1. An instance of Post-unblinding changes to a statistical analysis plan doom even highly promising therapeutic signals. — Regulators concluded the study failed to prove efficacy under its original pre-specified parameters, dismissing the positive results as post-hoc artifacts. ↩︎

Part of

This finding is an example of a pattern recurring across your work:

Revision history

  • Update the note with the newly released FDA briefing documents that dispute Capricor's Phase 3 success, detail the statistical analysis plan conflict, and describe the ensuing 65%+ stock crash ahead of the July 29 AdCom.
    · by the agent
  • Update the AdCom note to reflect the exact dates of the upcoming "showdown week": July 29 for Capricor's deramiocel (PDUFA August 22) and July 30 for Replimune's RP1 (PDUFA August 2), detailing the patient advocacy campaign and the contribution-of-effect clinical debates.
    · by the agent
  • Update the FDA regulatory pivot note to document the official scheduling and July 16, 2026 updates of the back-to-back CTGTAC meetings on July 29 and July 30 for Capricor's deramiocel and Replimune's RP1.
    · by the agent
  • Update the post-Makary FDA pivot storyline with Saol's SL1009 NDA resubmission, the upcoming July 29-30 AdCom details, and the FDA's persistent efficacy concerns on Replimune's RP1.
    · by the agent
  • Update the post-Makary FDA pivot note to reflect the confirmed AdCom dates of July 29 for Capricor's deramiocel and July 30 for Replimune's RP1, along with their respective PDUFA dates.
    · by the agent
  • Update Note on FDA regulatory pivot with Diamantas's disavowal of Makary's journal policies, the landmark Lipfendra approval under CNPV, and scheduled adcoms.
    · by the agent
  • Update the existing note with confirmed CTGTAC meeting details for Capricor and Replimune, and document Saol's SL1009 resubmission as a key post-Makary pivot event.
    · by the agent
  • Update the Post-Makary FDA Pivot finding with fresh details on the FDA's 2,200-person hiring initiative, CBER and CDER acting leadership, and Replimune's third BLA resubmission and upcoming late-July advisory committee meeting.
    · by the agent
  • Update with Saol Therapeutics' SL1009 resubmission on June 30, 2026, and details on the upcoming July CTGT Advisory Committee meetings for Capricor's deramiocel (July 29) and Replimune's RP1 (July 30) along with the post-Makary FDA leadership vacuum.
    · by the agent
  • Update the Post-Makary FDA Pivot note to include Saol Therapeutics' June 30, 2026 resubmission of SL1009 (DCA) for PDCD, illustrating the wider pattern of rapid biotech regulatory turnarounds.
    · by the agent
  • Update the existing post-Makary FDA pivot note with the newly confirmed late-July 2026 Advisory Committee dates for Capricor's deramiocel and Replimune's RP1.
    · by the agent
  • Update the post-Makary FDA pivot with the June 26 BLA resubmission acceptance for Replimune's RP1, Sobi's manufacturing-related CRL, and upcoming Q3 2026 AdCom milestones.
    · by the agent
  • Update the post-Makary FDA pivot with the June 26 BLA resubmission acceptance for Replimune's RP1, Sobi's manufacturing-related CRL, and upcoming Q3 2026 AdCom milestones.
    · by the agent
  • Update the post-Makary FDA pivot with the June 26 BLA resubmission acceptance for Replimune's RP1, Sobi's manufacturing-related CRL, and upcoming Q3 2026 AdCom milestones.
    · by the agent
  • Update note on FDA regulatory pivot to include Sarepta's sNDA acceptance, uniQure's BLA pathway, and upcoming Advisory Committees.
    · by the agent
  • Update the FDA regulatory pivot note with the acceptance of Capricor's and Replimune's BLA resubmissions, their scheduled advisory committee meetings, and the resignation of acting OTP director Vijay Kumar.
    · by the agent
  • Update the Post-Makary FDA Pivot note with the dual announcements on June 26, 2026: Capricor's deramiocel scheduled for a July 29 AdCom and August 22 PDUFA, and Replimune's RP1 BLA accepted as a Class 1 response with an August 2 PDUFA and late-July AdCom.
    · by the agent
  • Update with the official scheduling of AdComs for Capricor's deramiocel (July 29, 2026) and Replimune's RP1 (late July 2026) and the broader policy context under Acting FDA Commissioner Kyle Diamantas.
    · by the agent
  • Update with the official scheduling of AdComs for Capricor's deramiocel (July 29, 2026) and Replimune's RP1 (late July 2026) and the broader policy context under Acting FDA Commissioner Kyle Diamantas.
    · by the agent
  • Update with the official scheduling of AdComs for Capricor's deramiocel (July 29, 2026) and Replimune's RP1 (late July 2026) and the broader policy context under Acting FDA Commissioner Kyle Diamantas.
    · by the agent